Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Valneva
Thumbnail
May 16, 2022

Valneva and Synairgen remain Covid laggards

Thumbnail
April 20, 2022

Arcturus’s latecomer Covid vaccine elicits little interest

Article image
Vantage logo
March 08, 2022

Valneva nears the Chikungunya finish line

Article image
Vantage logo
March 01, 2022

Vaccine failure blows a hole in Pfizer's pipeline

Article image
Vantage logo
February 04, 2022

Another step backwards for Valneva

The group’s Covid vaccine, as well as Sanofi and Glaxosmithkline’s jab, might not reach Europe for some time.

Article image
Vantage logo
January 20, 2022

Valneva's Omicron splash masks a delay in Europe

Article image
Vantage logo
December 07, 2021

Mitsubishi's Medicago heads for the Covid-19 booster queue

The Canadian subsidiary claims success in its pivotal trial, though capacity restraints will limit the jab’s role for now.

Article image
Vantage logo
December 06, 2021

Bavarian Nordic goes it alone, for now

Phase 3 in RSV will begin without a partner, while decent Covid-19 booster data pave the way for pivotal development.

Article image
Vantage logo
November 29, 2021

Biggest unpartnered assets: Argenx nears crunch time

Amid cautionary tales of other highly valued unpartnered assets, efgartigimod approaches its US date with destiny.

Article image
Vantage logo
October 18, 2021

Valneva scores a pyrrhic trial win

The group’s Covid-19 vaccine is on course for UK approval – but the UK doesn’t want it.

Article image
Vantage logo
September 13, 2021

Valneva falls as UK contract axe falls

Valneva might have to look beyond the UK for vaccine sales after today's contract termination.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

April 20, 2022

Genetic Medicine: The Next Generation

March 18, 2022

PD(L)anner - March 2022

View more...

Editor's Picks

Vantage logo
May 05, 2022

Bristol needs to get fresh

Vantage logo
May 04, 2022

The next generation of diabetes technology

Vantage logo
April 25, 2022

Nkarta: at least as good as Fate, at a tenth of the price

Vantage logo
April 26, 2022

How Gal appointment could influence strategy at Novartis

Vantage logo
May 01, 2020

US FDA approval tracker: April

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.